OakChart

BioCardia Inc

BCDAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.9217-0.0085 (-0.91%)
2026-11-11 22:05 CET
Market cap
14.08 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.34 USD m
Free cash flow, TTM
-7.57 USD m
EPS diluted, TTM
-0.76
P/E
-
Compare

Price

BCDA against its 20, 50 and 200-day averages
2050200beatearnings
0.751.001.251.501.7575.6M151.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BCDAclose 0.9220-day 0.9250-day 1.02200-day 1.060.9252w high52w low

48.8% under the 52-week high of 1.80 on 5 Jun 2026. 52-week low 0.75 on 28 Jul 2026. Last 15 sessions, 19.6% high to low

Volume 0.27× normal · the line is the 50-bar volume average

Profile

BCDA
52-week range, 16% of the way up
0.751.80

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Employees17
IPONov 13, 1996
Beta0.64
ATR, 14d0.08
Rel volume0.27
Short float6.37%
Insider own23.74%
Inst own8.53%

Snapshot

6 groups

Valuation

Index-
Market Cap13.95M
Enterprise Value10.12M
Income-7.34M
Sales0.00M
Book/sh0.18
Cash/sh0.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPONov 13, 1996

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.12
P/C3.39
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.09
Current Ratio2.09
Debt/Eq0.11
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.76
EPS next Y-0.52
EPS next Q-0.13
EPS this Y48.78%
EPS next Y18.25%
EPS next 5Y31.52%
EPS past 3/5Y50.34% 43.92%
Sales past 3/5Y- -
EPS Y/Y TTM63.72%
Sales Y/Y TTM-100.00%
EPS Q/Q67.06%
Sales Q/Q-
EarningsNov 12 AMC
EPS/Sales Surpr.27.78% -

Ownership

Insider Own23.74%
Insider Trans4.76%
Inst Own8.53%
Inst Trans9.61%
ROA-214.47%
ROE-1803.19%
ROIC-271.81%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.09%
SMA50-9.20%
SMA200-12.96%
Trades-

Technical

Shs Outstand14.98M
Shs Float11.54M
Short Float6.37%
Short Ratio3.44
Short Interest0.74M
52W High1.80 -48.79%
52W Low0.75 22.89%
Volatility9.64% 9.29%
ATR (14)0.08
RSI (14)47.25
Beta0.64
Rel Volume0.27
Avg Volume213.78K
Volume58,166

Performance

Perf Week0.94%
Perf Month-6.93%
Perf Quarter-0.78%
Perf Half Y-13.86%
Perf YTD-26.26%
Perf Year-30.70%
Perf 3Y-84.24%
Perf 5Y-97.59%
Perf 10Y-99.63%
Recom1.00
Target Price15.50
Prev Close0.93
Price0.92
Change %-0.91%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Apr 16, 2021DowngradeDDawson JamesBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
CAPRCapricor Therapeutics Inc652.32M
LGVNLongeveron Inc10.52M
MESOMesoblast Ltd ADR1.78B
TNYATenaya Therapeutics Inc84.61M
CELZCreative Medical Technology Holdings Inc4.93M
PLURPluri Inc15.13M
BRTXBioRestorative Therapies Inc2.15M
LSTALisata Therapeutics Inc12.96M
CVKDCadrenal Therapeutics Inc5.18M
KARDKardigan Inc1.47B

Insider trading

latest 14 of 34
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Altman PeterPresident and CEOOct 16 '26Buy0.95300285385,385Oct 20 05:42 PM
Altman PeterPresident and CEOOct 15 '26Buy0.95200190385,085Oct 20 05:42 PM
Altman PeterPresident and CEOSep 29 '26Buy1.031,0001,030384,885Sep 30 06:51 PM
Altman PeterPresident and CEOSep 23 '26Buy1.051,9001,995383,885Sep 23 08:14 PM
Altman PeterPresident and CEOSep 03 '26Buy1.09800872381,985Sep 04 09:30 PM
Altman PeterPresident and CEOAug 17 '26Buy0.935,4005,022381,115Aug 18 12:14 PM
Altman PeterPresident and CEOAug 13 '26Buy0.921,9001,748375,785Aug 13 05:43 PM
Altman PeterPresident and CEOJul 29 '26Buy0.785,0003,900373,885Jul 29 09:05 PM
Altman PeterPresident and CEOJul 17 '26Buy0.83500415368,885Jul 20 04:16 PM
Altman PeterPresident and CEOJul 14 '26Buy0.882,8002,464366,885Jul 15 04:40 PM
Altman PeterPresident and CEOJul 15 '26Buy0.861,5001,290368,385Jul 15 04:40 PM
Altman PeterPresident and CEOJul 08 '26Buy0.975,5005,335367,485Jul 10 06:18 PM
Altman PeterPresident and CEOJul 10 '26Buy0.941,000940369,485Jul 10 06:18 PM
Altman PeterPresident and CEOJul 09 '26Buy0.901,000900368,485Jul 10 06:18 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 200
  • BioCardia's Japan Filing Clock Meets A Shrinking Cash Cushion In Third-Quarter Report (Earnings Whispers)
  • BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026 (GlobeNewswire) +6.19%
  • BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application (GlobeNewswire)
  • BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter (GlobeNewswire)
  • BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
  • BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix Catheter (GlobeNewswire)
  • BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission (GlobeNewswire)
  • BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval (GlobeNewswire)
  • BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... (GuruFocus.com) +5.56%
  • BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results (GlobeNewswire) -5.59%
  • BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 (GlobeNewswire)
  • BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities (GlobeNewswire)
  • BioCardia Announces $4.4 Million Financing (GlobeNewswire) -10.68%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.130--0.002
2026Q22026-08-12-0.130-0.180-0.1300.000.002
2026Q12026-05-15-0.210-0.165-0.2090.000.002
2025Q42026-03-240.000-0.170-0.1850.000.002
2025Q32025-11-12-0.240-0.230-0.2360.000.002
2025Q22025-08-11-0.400-0.500-0.4050.000.001
2025Q12025-05-14-0.590--0.5850.00--
2024Q42025-03-26-0.060-0.625-0.4990.030.022
2024Q32024-11-13-0.610-1.190-0.6140.000.201
2024Q22024-08-13-0.880-0.100-0.8770.000.051
2024Q12024-05-14-1.350--1.3530.06--
2023Q42024-03-27-1.350-1.125-1.3130.020.192
2023Q32023-11-08-1.800-1.800-1.7860.360.052
2023Q22023-08-09-2.550-2.350-2.5200.040.183
2023Q12023-05-10-2.550-2.400-2.6030.060.343
2022Q42023-03-29-2.550-2.700-2.4790.110.153

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-43.200--43.2000.48-
2018FY-48.600--49.2020.63-
2019FY-39.150-34.850-39.0900.710.58
2020FY-22.200-24.263-22.2420.150.27
2021FY-11.250-9.788-11.1921.020.62
2022FY-10.050-10.000-10.0791.351.27
2023FY-8.250-5.475-8.1950.480.70
2024FY-2.900-3.110-2.8960.060.09
2025FY-1.230-1.200-1.2300.000.00
2026FY--0.630--0.00
2027FY--0.515--0.00
2028FY--0.395--4.15

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-231000.000.000.00
2026Q3S2026-08-132000.000.000.00
2026Q3S2026-08-122000.000.000.00
2026Q3S2026-05-152000.000.000.00
2026Q3S2026-03-251000.000.000.00
2026Q3R2026-10-27100-0.11-0.11-0.11
2026Q3R2026-08-13110-0.11-0.11-0.11
2026Q3R2026-08-12100-0.12-0.12-0.12
2026Q3R2026-05-15100-0.12-0.12-0.12
2026Q3E2026-10-27200-0.13-0.15-0.11
2026Q3E2026-08-13220-0.13-0.15-0.11
2026Q3E2026-08-12201-0.15-0.18-0.12
2026Q3E2026-06-08201-0.15-0.18-0.12
2026Q3E2026-06-05200-0.15-0.17-0.12

Estimate history

EPS, annual-43.2-49.202-39.09-22.242-11.192-10.079-8.195-2.896-1.234-0.763
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.877-0.614-0.499-0.585-0.405-0.236-0.185-0.209-0.133
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.4790.6250.710.1451.0151.3520.4770.05800
Period201720182019202020212022202320242025TTM
Sales, quarterly0.00300000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.2830.3230.4551.0861.1251.3381.5784.60110.75614.984
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.1244.5244.6014.6825.50510.60910.75610.9414.984
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.060.481.351.010.140.710.62
Cost of Goods Sold Incl. D&A0.540.510.550.410.380.640.570.910.52
Gross Profit-0.54-0.51-0.490.070.970.38-0.42-0.200.11
Selling, General and Administrative Excl. Other6.857.777.5111.7112.8813.0115.1014.0114.21
Research and Development4.184.944.327.648.838.569.818.568.45
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.39-8.28-8.00-11.64-11.90-12.63-15.53-14.21-14.10
Interest Expense0.000.000.000.000.000.000.000.110.00
Unusual Expense0.000.000.000.000.000.00-0.510.470.00
Net Income Before Taxes-7.34-8.23-7.95-11.57-11.91-12.62-15.00-14.71-13.99
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-7.34-8.23-7.95-11.57-11.91-12.62-15.00-14.71-13.99
Net Income From Continuing Operations-7.34-8.23-7.95-11.57-11.91-12.62-15.00-14.71-13.99
Net Income-7.34-8.23-7.95-11.57-11.91-12.62-15.00-14.71-13.99
EPS (Recurring)-0.61-1.23-2.90-8.19-10.08-11.19-22.77-38.22-49.20
EPS (Basic, Before Extraordinaries)-0.76-1.23-2.90-8.19-10.08-11.19-22.24-39.09-49.20
EPS (Diluted)-0.76-1.23-2.90-8.19-10.08-11.19-22.24-39.09-49.20
EBITDA-6.85-7.77-7.45-11.23-11.52-11.99-14.96-13.66-14.01
Non-Operating Income (Expense)0.050.050.060.07-0.010.010.020.090.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.380.430.741.031.181.662.952.722.77
Price To Sales Ratio--103.1329.4927.3932.34241.4529.2673.69
Gross Margin---846.5513.8472.1236.95-293.10-28.0317.28
Operating Margin---13,794.83-2,441.09-880.25-1,244.33-10,709.66-2,001.83-2,256.32
Net Margin---13,700.00-2,425.79-880.70-1,243.65-10,347.59-2,071.69-2,237.92
Shares Outstanding14.9810.764.601.581.341.121.090.460.32
Market Capitalization14.0814.089.9914.3637.2932.7356.3925.1252.33

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.120.180.110.100.110.110.11
Gross Profit-0.12-0.12-0.18-0.11-0.10-0.11-0.11-0.11
Selling, General and Administrative Excl. Other1.502.141.831.381.952.622.211.65
Research and Development0.891.231.120.931.361.521.350.93
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.62-2.27-2.01-1.49-2.05-2.73-2.32-1.76
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.61-2.26-1.98-1.48-2.05-2.71-2.30-1.74
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.61-2.26-1.98-1.48-2.05-2.71-2.30-1.74
Net Income From Continuing Operations-1.61-2.26-1.98-1.48-2.05-2.71-2.30-1.74
Net Income-1.61-2.26-1.98-1.48-2.05-2.71-2.30-1.74
EPS (Recurring)-0.13-0.21-0.18-0.24-0.40-0.59-0.50-0.61
EPS (Basic, Before Extraordinaries)-0.13-0.21-0.18-0.24-0.41-0.58-0.50-0.61
EPS (Diluted)-0.13-0.21-0.18-0.24-0.41-0.58-0.50-0.61
EBITDA-1.50-2.14-1.83-1.38-1.95-2.62-2.21-1.65
Non-Operating Income (Expense)0.010.010.030.010.000.010.030.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.110.090.080.100.170.180.18
Price To Sales Ratio-----3,924.95172.93124.25
Shares Outstanding14.9810.9410.7610.615.504.684.604.52
Market Capitalization14.0813.2413.2713.6910.1011.899.9910.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2.502.371.107.3612.8721.415.585.3612.69
Short Term Receivables0.020.000.060.200.150.850.150.270.10
Inventories0.000.000.000.000.000.000.000.140.19
Other Current Assets0.220.250.290.300.460.400.640.450.34
Total Current Assets2.732.621.467.8613.4822.666.386.2213.31
Net Property, Plant & Equipment0.510.931.351.762.060.711.250.140.17
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Other Assets0.170.170.170.170.170.050.050.050.05
Total Assets3.413.722.999.7915.7223.427.686.4213.54
Short Term Debt Incl. Current Port. of LT Debt0.440.390.330.320.240.610.530.000.00
Accounts Payable0.640.390.890.680.510.750.911.020.90
Other Current Liabilities1.351.552.382.592.972.892.561.531.43
Total Current Liabilities2.432.323.613.583.714.254.002.552.33
Long Term Debt0.090.570.981.321.630.000.610.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.690.080.08
Total Liabilities2.522.894.594.905.344.255.312.622.41
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity0.900.84-1.604.8910.3819.182.373.7911.12
Total Shareholders Equity0.900.84-1.604.8910.3819.182.373.7911.12
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity0.900.84-1.604.8910.3819.182.373.7911.12
Total Liabilities & Stockholders Equity3.413.722.999.7915.7223.427.686.4213.54
Book Value Per Share0.080.18-1.023.659.2217.655.2111.7439.30
Tangible Book Value Per Share0.080.18-1.023.659.2217.655.2111.7439.30
Full-Time Employees172020363529242724
Price to Book Ratio5.163.58-21.769.103.152.9410.6013.806.50
Return on Assets-230.57-236.81-181.08-93.35-64.50-96.48-208.71-140.19-69.11
Return on Equity-950.12--703.62-155.98-85.43-139.27-477.41-187.53-77.64
Return on Invested Capital-838.74-566.36--191.80-105.14-78.24-492.93-368.86-110.63
Quick Ratio1.121.130.402.193.635.331.592.395.63
Current Ratio1.121.130.402.193.635.331.592.445.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-7.34-8.23-7.95-11.57-11.91-12.62-15.00-14.71-13.99
Depreciation0.540.510.550.410.380.640.570.550.09
Other Funds (Non Cash)0.320.430.711.031.181.682.453.302.77
Funds from Operations-6.48-7.29-6.69-10.13-10.35-10.30-11.99-10.85-11.12
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.08-0.14-1.200.15-0.21-0.06-0.361.410.06
Cash from Operating Activities-7.56-7.44-7.89-9.97-10.56-10.37-12.36-9.45-11.07
Capital Expenditures-0.01-0.01-0.01-0.01-0.07-0.12-0.03-0.15-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.01-0.01-0.01-0.07-0.12-0.03-0.15-0.07
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.917.769.303.735.121.9527.869.193.80
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.917.769.303.735.121.9527.869.193.80
Proceedsfrom Stock Options10.877.769.303.735.121.9427.86-1.260.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.510.620.00
Change in Long Term Debt0.000.000.000.000.000.000.510.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.510.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.20-0.20-0.140.000.000.00-0.160.000.00
Other Financing Activities Uses-0.20-0.20-0.140.000.000.00-0.160.000.00
Cash from Financing Activities10.717.579.163.735.121.9528.219.823.80
Net Change in Cash3.140.121.27-6.26-5.51-8.5415.820.23-7.33
Free Cash Flow-7.57-7.44-7.89-9.99-10.63-10.48-12.39-9.59-11.13
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.120.952.505.290.980.95
Short Term Receivables0.030.020.020.000.010.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.150.170.220.080.210.22
Total Current Assets4.301.142.735.371.201.17
Net Property, Plant & Equipment0.290.400.510.610.720.82
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.170.170.170.170.170.17
Total Assets4.751.713.416.152.092.17
Short Term Debt Incl. Current Port. of LT Debt0.290.410.440.430.410.40
Accounts Payable0.540.820.641.081.230.82
Other Current Liabilities1.221.551.351.802.002.02
Total Current Liabilities2.062.782.433.313.643.23
Long Term Debt0.000.000.090.210.330.45
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.062.782.523.523.983.69
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2.70-1.070.902.63-1.89-1.52
Total Shareholders Equity2.70-1.070.902.63-1.89-1.52
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2.70-1.070.902.63-1.89-1.52
Total Liabilities & Stockholders Equity4.751.713.416.152.092.17
Book Value Per Share0.18-0.100.080.25-0.34-0.32
Tangible Book Value Per Share0.18-0.100.080.25-0.34-0.32
Full-Time Employees--17---
Price to Book Ratio5.1614.545.05-3.77-6.0113.96
Return on Assets-214.47-400.98-230.57-137.58-353.24-346.38
Return on Equity-1,803.19--950.12-317.47--
Return on Invested Capital-59.74--202.24-52.26--
Quick Ratio2.090.411.121.620.330.36
Current Ratio2.090.411.121.620.330.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.61-2.26-1.98-1.48-2.05-2.71
Depreciation0.120.120.180.110.100.11
Other Funds (Non Cash)0.110.110.090.010.160.17
Funds from Operations-1.38-2.02-1.71-1.36-1.78-2.43
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.350.36-0.78-0.310.130.81
Cash from Operating Activities-1.74-1.66-2.50-1.67-1.65-1.62
Capital Expenditures0.00-0.00-0.010.00-0.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.00-0.010.00-0.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.900.12-0.095.981.680.20
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.900.12-0.095.981.680.20
Proceedsfrom Stock Options4.860.12-0.095.981.680.20
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.200.000.000.00
Other Financing Activities Uses0.000.00-0.200.000.000.00
Cash from Financing Activities4.900.12-0.295.981.680.20
Net Change in Cash3.17-1.54-2.794.310.03-1.42
Free Cash Flow-1.74-1.66-2.50-1.67-1.65-1.62

Revenue breakdown

Total Biological Products, (No Diagnostic Substances) revenue2024: 58.00K
United States2024: 58.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.37%0.7M11.5M241.24K
2026-10-155.88%0.7M11.5M259.96K
2026-09-305.37%0.6M11.5M321.66K
2026-09-1514.97%0.9M5.8M499.46K
2026-08-318.72%1.0M11.6M3.02M
2026-08-148.92%1.0M11.6M3.05M
2026-07-3110.85%1.1M10.2M3.10M
2026-07-1513.17%1.3M10.2M3.12M
2026-06-303.68%0.4M10.1M3.00M
2026-06-154.17%0.4M10.5M2.71M
2026-05-294.16%0.3M7.9M162.97K
2026-05-153.06%0.2M8.0M152.78K
2026-04-302.14%0.2M7.7M66.98K
2026-04-153.59%0.2M4.9M66.61K
2026-03-312.32%0.2M7.7M67.83K
2026-03-132.59%0.2M7.4M79.70K
2026-02-272.94%0.2M7.4M77.27K
2026-02-133.18%0.2M7.4M79.72K
2026-01-304.89%0.2M4.8M79.97K
2026-01-154.52%0.2M4.8M94.49K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-068-KCurrent report2026-11-06SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-078-KCurrent report2026-10-07SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-238-KCurrent report2026-09-23SEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-248-KCurrent report2026-08-24SEC
2026-08-218-KCurrent report2026-08-19SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-154Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10475200
2026-093.90K300
2026-086.77K200
2026-0720.45K800
2026-06109.88K500
2026-0512.02K400
2026-046.78K300
2026-031.11K200
2026-025.65K100
2026-011.19K200
2025-121.44K200
2025-110000

Institutional holders

Manager% owned
CM Management, LLC2.02%
CITIGROUP INC1.82%
VANGUARD CAPITAL MANAGEMENT LLC0.84%
Pingora Partners LLC0.81%
GEODE CAPITAL MANAGEMENT, LLC0.69%
VANGUARD FIDUCIARY TRUST CO0.45%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.26%
BROWN ADVISORY INC0.24%
StoneX Group Inc.0.22%
CITADEL ADVISORS LLC0.15%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.46%
Fidelity Extended Market Index Fund0.39%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.37%
Fidelity Series Total Market Index Fund0.07%
Fidelity Total Market Index Fund0.02%
Fidelity Nasdaq Composite Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. BCDA. Cached 15 minutes.